MRI target delineation may reduce long-term toxicity after prostate radiotherapy

Abstract Background and purpose. Aiming for minimal toxicity after radical prostate cancer (PC) radiotherapy (RT), magnetic resonance imaging (MRI) target delineation could be a possible benefit knowing that clinical target volumes (CTV) are up to 30% smaller, when CTV delineation on MRI is compared to standard computed tomography (CT). This study compares long-term toxicity using CT or MRI delineation before PC RT. Material and methods. Urinary and rectal toxicity assessments 36 months after image-guided RT (78 Gy) using CTC-AE scores in two groups of PC patients. Peak symptom score values were registered. One group of patients (n = 72) had standard CT target delineation and gold markers as fiducials. Another group of patients (n = 73) had MRI target delineation and a nickel-titanium stent as fiducial. Results. At 36 months no difference in overall survival (92% in both groups, p = 0.29) or in PSA-relapse free survival was found between the groups (MRI = 89% and CT = 94%, p = 0.67). A significantly smaller CTV was found in the MRI group (p = 0.02). Urinary retention and frequency were significantly reduced in the MRI group (p = 0.03 in the matter of both). The overall urinary and rectal toxicity did not differ between the two groups. Conclusion. MRI delineation leads to a significantly reduced CTV. Significantly lower urinary frequency and urinary retention toxicity scores were observed following MRI delineation. The study did not find significant differences in overall urinary or rectal toxicity between the two groups. PSA-relapse survival did not differ between the two groups at 36 months.

[1]  M. V. van Herk,et al.  Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: results from a randomized trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  C. Koning,et al.  Improved tumour control probability with MRI-based prostate brachytherapy treatment planning , 2013, Acta oncologica.

[3]  J. Birt,et al.  Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data , 2013, International journal of clinical practice.

[4]  Eva Bezak,et al.  Current challenges in clinical target volume definition: Tumour margins and microscopic extensions , 2012, Acta oncologica.

[5]  Franck Bonnetain,et al.  Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  D. T. Arp,et al.  Urethra sparing - potential of combined Nickel-Titanium stent and intensity modulated radiation therapy in prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  R. Fisker,et al.  Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer , 2011, Acta oncologica.

[8]  Ansgar Malich,et al.  Definition of the CTV Prostate in CT and MRI by Using CT–MRI Image Fusion in IMRT Planning for Prostate Cancer , 2011, Strahlentherapie und Onkologie.

[9]  Mary Feng,et al.  Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. , 2010, International journal of radiation oncology, biology, physics.

[10]  C. Fiorino,et al.  Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  P. Xia,et al.  Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. , 2009, International journal of radiation oncology, biology, physics.

[12]  Frederik Wenz,et al.  Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT™ (B-mode acquisition and targeting system) for prostate cancer , 2008, Strahlentherapie und Onkologie.

[13]  J. Lebesque,et al.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[14]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[15]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[16]  David Wilkins,et al.  A study of prostate delineation referenced against a gold standard created from the visible human data. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[18]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[19]  M. Zelefsky,et al.  Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[20]  M. Hoogeman,et al.  Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[21]  George Starkschall,et al.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[22]  Randall K Ten Haken,et al.  Daily prostate targeting using implanted radiopaque markers. , 2001, International journal of radiation oncology, biology, physics.

[23]  K. Langen,et al.  Organ motion and its management. , 2001, International journal of radiation oncology, biology, physics.

[24]  M van Herk,et al.  Definition of the prostate in CT and MRI: a multi-observer study. , 1999, International journal of radiation oncology, biology, physics.

[25]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[26]  C. Perez,et al.  Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. , 1994, International journal of radiation oncology, biology, physics.